|Bid||38.00 x 800|
|Ask||42.00 x 1100|
|Day's Range||39.54 - 41.32|
|52 Week Range||38.78 - 80.92|
|Beta (3Y Monthly)||1.51|
|PE Ratio (TTM)||31.87|
|Earnings Date||Oct 28, 2019 - Nov 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.40|
The best health care stocks to watch have several commonalities including a streak of earnings growth. It's important to keep tabs on high-ranking health care stocks with strong metrics.
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that Manish Wadhwa, M.D., F.H.R.S. (Fellow of the Heart Rhythm Society), has been named Chief Medical Officer. Dr. Wadhwa will lead the company’s clinical strategy and operations, reporting to Joseph H. Capper, President and Chief Executive Officer. Dr. Wadhwa, co-founder of Geneva Health Solutions, joined BioTelemetry in March 2019 as part of the company’s acquisition of Geneva.
BioTelemetry (BEAT) delivered earnings and revenue surprises of 17.78% and 0.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Exceeds Expectations Achieves Record Revenue and Adjusted EBITDA MALVERN, Pa., July 30, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology.
BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that it has acquired ADEA Medical AB, an early-stage Swedish medical technology company that delivers remote health services in the Nordics. The acquisition is aligned with BioTelemetry’s longer-term strategy to increase its international footprint and offer its products and services to physicians and patients in the Nordics and other parts of Europe. BioTelemetry advances health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner.
BioTelemetry (BEAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MALVERN, Pa., July 19, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its second quarter 2019 earnings on Tuesday, July 30 at 4:00 PM Eastern Time. The BioTelemetry.
In 2010 Joe Capper was appointed CEO of BioTelemetry, Inc. (NASDAQ:BEAT). This analysis aims first to contrast CEO...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Itamar Medical Ltd. (NASDAQ and TASE:ITMR), a company that develops, manufacturers and markets non-invasive diagnostic devices for sleep apnea with a focus on the cardiology market, and BioTel Heart, a division of BioTelemetry, Inc. (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced an expanded collaboration to make Itamar Medical’s Total Sleep Solution available to select BioTel Heart cardiology customers in the United States. The collaboration is designed to respond to the growing demand for home sleep apnea testing among cardiologists, who recognize effective sleep apnea management as a critical strategy for improving health in patients with cardiac disease.
BioTelemetry (BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that Joseph H. Capper, President and CEO, has been awarded the 2019 Healthcare CEO of the Year Award by the Philadelphia Alliance for Capital and Technologies, or PACT. The Healthcare CEO of the Year Award recognizes leaders for their management accomplishments and philosophy, including the communication of a vision and goals as achieved by the company. “Each day we work with our customers and business partners to make a difference in the lives of our patients and communities,” said Joseph H. Capper, President and CEO of BioTelemetry.
Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 25) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ...
On a per-share basis, the Malvern, Pennsylvania-based company said it had profit of 32 cents. Earnings, adjusted for one-time gains and costs, were 42 cents per share. The results met Wall Street expectations. ...
Achieves Record Quarterly Revenue Raises Full Year 2019 Guidance MALVERN, Pa., April 25, 2019 -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology.